During the current grant period, CCSG developmental funds were used to support the mission of the Cancer Center in 2 categories critical to the advancement of its goals: 1) additional faculty recruitment in disciplines related to the strategic vision of the Center and 2) pilot project grants to stimulate cross-disciplinary research involving population science. Both categories have proven rich opportunities for the Center to strengthen and diversify its research portfolio. Funds requested to support faculty recruitment in strategic areas have enabled the Center to attract top talent by providing a start-up/transition package that has enabled 8 new recruits to have the resources to immediately develop their research programs. Since their arrival at MSK, these 8 investigators have received $23.8M in peer-reviewed funding and produced over 25 manuscripts from their laboratories. Funds requested to support cross-disciplinary pilot projects involving PSR and other Center programs supported 16 projects, covering the broad spectrum of areas of population research that characterize the PSR Program, with multiple awards in each of PSR?s major programmatic themes: 1) cancer etiology and risk; 2) health behavior and symptom control; and 3) health care delivery, access and disparities. The projects were multidisciplinary as a requirement, and in many cases creative cross-disciplinary interactions were formed, matching population scientists with basic laboratory investigators or clinical investigators. Results have been exciting, with 3 of our junior investigators receiving their first NIH grants as a result of the pilot funds provided by this program. To date, 8 peer-reviewed grants have been awarded stemming from the research conducted in these pilot projects (4 NCI, 2 other NIH, 2 ACS). The total direct cost from these grants is $8,816,229. Building on the success in the current grant period, the Center proposes to continue its program in PSR Pilot Project Funding. We also propose a second faculty recruitment initiative to support the recruitment and integration of faculty with expertise in computational biology. This initiative will build on recent, strategic infrastructure investments in computational biology made by MSK.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084840
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kavaler, Joshua; Duan, Hong; Aradhya, Rajaguru et al. (2018) miRNA suppression of a Notch repressor directs non-neuronal fate in Drosophila mechanosensory organs. J Cell Biol 217:571-583
Bosse, Tjalling; Nout, Remi A; McAlpine, Jessica N et al. (2018) Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 42:561-568
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Scordo, Michael; Morjaria, Sejal M; Littmann, Eric R et al. (2018) Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1914-1919
Byron, Sara A; Tran, Nhan L; Halperin, Rebecca F et al. (2018) Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res 24:295-305
Zarnegar, Sara; Durham, Benjamin H; Khattar, Pallavi et al. (2018) Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 65:
Francis, Jasmine H; Slakter, Jason S; Abramson, David H et al. (2018) Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab. Am J Ophthalmol Case Rep 11:49-51
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795

Showing the most recent 10 out of 8799 publications